Premium
Human models for COVID‐19 research
Author(s) -
Woodall Maximillian N. J.,
Masonou Tereza,
Case KatieMarie,
Smith Claire M.
Publication year - 2021
Publication title -
the journal of physiology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.802
H-Index - 240
eISSN - 1469-7793
pISSN - 0022-3751
DOI - 10.1113/jp281499
Subject(s) - covid-19 , drug development , disease , human disease , intensive care medicine , medicine , computational biology , drug , virology , biology , infectious disease (medical specialty) , pathology , pharmacology , outbreak
Currently, therapeutics for COVID‐19 are limited. To overcome this, it is important that we use physiologically relevant models to reproduce the pathology of infection and evaluate the efficacy of antiviral drugs. Models of airway infection, including the use of a human infection challenge model or well‐defined, disease relevant in vitro systems can help determine the key components that perpetuate the severity of the disease. Here, we briefly review the human models that are currently being used in COVID‐19 research and drug development.